The recent FDA approval of icotrokinra (Icotyde; Johnson & Johnson), a first-in-class oral interleukin-23 (IL-23) receptor antagonist, has potentially opened the door to a new way of treating moderate-to-severe plaque psoriasis in adults and adolescents aged 12 years and older weighing at least 40 kg.
Game Changer
The once-daily oral peptide, the first of its kind, offers a mechanistically distinct option in a therapeutic landscape largely defined by injectable biologics. Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health, sees the new treatment as a potential “game changer” for many adults and adolescents with plaque psoriasis.
“Moderate to severe plaque psoriasis has historically had limited oral treatment options that effectively balance efficacy with acceptable safety and tolerability,” Dr. Stein Gold explained. “This therapy offers patients an additional oral option with clinical data suggesting meaningful efficacy and a favorable safety and tolerability profile.”
Currently available IL-23 inhibitors target the cytokine itself, whereas icotrokinra selectively blocks the IL-23 receptor, an approach that may offer more direct interruption of the inflammatory signaling cascade. Combined with the convenience of oral administration, icotrokinra provides a dual advantage over earlier treatment options: mechanistic precision and ease of use, which may influence earlier adoption of systemic therapy in appropriate patients.
Meeting the Needs of Psoriasis Patients
More than 8 million individuals in the United States are affected by psoriasis, and those with moderate-to-severe disease often require systemic treatment. Despite advances, clinicians continue to navigate challenges related to adherence, patient preferences, and treatment fatigue, particularly with injectable agents.
While guidance from the International Psoriasis Council recommends transitioning to systemic therapy after failure of two adequate topical treatment cycles, concerns about safety, administration burden, and patient reluctance can delay escalation.
“Finding the right treatment can take time, during which people with psoriatic disease should be considering multiple factors, from efficacy to safety to how the treatment fits into their everyday life,” said Leah M. Howard, JD, president and CEO of the National Psoriasis Foundation. “The approval of a novel systemic therapy changes the conversation about treatment options for our community.”
The approval was based on the ICONIC clinical development program, which included four phase three trials enrolling approximately 2,500 patients. Notable for its breadth, the program evaluated both adults and adolescents, as well as patients with involvement of high-impact areas such as the scalp and genital regions.
In head-to-head superiority trials against an active comparator, icotrokinra demonstrated robust efficacy, with approximately 70% of patients achieving Investigator’s Global Assessment (IGA) scores of 0/1 (clear or almost clear skin at week 16 and around 55% achieving a Psoriasis Area and Severity Index (PASI) 90 response at week 16.
These results are consistent with the high levels of skin clearance observed with IL23 pathway inhibition achieved using injectables.
From a safety perspective, rates of adverse reactions were within 1.1% of placebo through week 16, and no new safety signals were identified through 52 weeks. Longer-term surveillance will be essential, but these findings suggest a favorable tolerability profile consistent with targeted immunomodulatory therapy.
Shifting Expectations
The FDA approval of icotrokinra underscores a broader evolution toward targeted, patient-friendly therapies in dermatology. By combining oral administration with high efficacy and a favorable safety profile, this new therapy represents meaningful progress in closing the longstanding gap between convenience and clinical outcomes.
For clinicians, the availability of an oral IL-23 receptor antagonist introduces new flexibility in tailoring treatment strategies.
Icotrokinra’s role in psoriasis management will become clearer as real-world experience accumulates, but early evidence suggests it may significantly expand what is achievable for patients with moderate-to-severe disease.
